AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 152 filers reported holding AKERO THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 1.85 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,353,944 | +61.5% | 46,539 | +22.2% | 0.00% | 0.0% |
| Q2 2023 | $1,457,323 | 0.0% | 38,090 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,457,323 | -26.1% | 38,090 | +5.9% | 0.00% | 0.0% |
| Q4 2022 | $1,971,102 | -99.8% | 35,969 | +46.2% | 0.00% | – |
| Q3 2022 | $837,937,000 | +161.8% | 24,609 | -27.3% | 0.00% | – |
| Q2 2022 | $320,090,000 | +21.0% | 33,872 | +81.7% | 0.00% | – |
| Q1 2022 | $264,502,000 | +24.9% | 18,640 | +155.3% | 0.00% | – |
| Q1 2021 | $211,773,000 | -2.3% | 7,300 | -13.1% | 0.00% | – |
| Q4 2020 | $216,720,000 | -16.2% | 8,400 | 0.0% | 0.00% | – |
| Q3 2020 | $258,636,000 | – | 8,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $168,435,000 | 13.00% |
| venBio Partners LLC | 2,444,311 | $63,063,000 | 5.57% |
| Versant Venture Management, LLC | 777,727 | $20,065,000 | 2.08% |
| Vivo Capital, LLC | 633,426 | $16,342,000 | 0.73% |
| Redmile Group, LLC | 2,322,557 | $59,922,000 | 0.73% |
| Boxer Capital, LLC | 831,495 | $21,453,000 | 0.69% |
| Integral Health Asset Management, LLC | 85,000 | $2,193,000 | 0.65% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 35,179 | $908,000 | 0.53% |
| HighVista Strategies LLC | 27,739 | $716,000 | 0.46% |
| Cormorant Asset Management, LP | 742,549 | $19,158,000 | 0.46% |